Flow Cytometry Indicates Treatment Response in AML For children with acute myeloid leukemia (AML), minimal residual disease (MRD) activity, as measured using flow cytometry, is a good indicator of ...

As AML bulk cells are heterogeneous ... We have demonstrated for the first time that MRD assessment by flow cytometry at aplasia is feasible and has an independent prognostic value next to ...

In acute myeloid leukemia (AML), MRD is typically assessed by using flow cytometry and, at some centers, by quantifying NPM1 transcripts — an independent and powerful prognosticator of AML.

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute ... multiparameter flow-cytometry (MFC), quantitative polymerase chain ...

Relapsed AML is a dangerous and deadly thing. And obviously what we would love to do is never have a patient relapse. There's a lot of discussion of MRD, or measurable residual disease ...

A new single-tube flow panel for the development of AML therapies ... and evaluating measurable residual disease (MRD) in AML samples. The new panel unleashes the power of Cytek’s Full Spectrum ...

Pharmaceuticals announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly ...

NewsVoir New Delhi [India], June 16: To achieve a consensus on a suitable panel and analysis strategy to report Acute Myeloid Leukemia - Measurable Residual Disease (AML-MRD) by flow cytometry, BD ...